EU approves Oncaspar (pegaspargase) as therapy for acute lymphoblastic leukaemia- Baxalta
Baxalta announced that the European Commission has granted Marketing Authorization for use of Oncaspar (pegaspargase) as a combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
With this approval, Baxalta is authorized to market Oncaspar in the 28 member countries of the European Union (EU), as well as Iceland, Liechtenstein and Norway. The drug is already licensed to market in Argentina, Belarus, Germany, Kazakhstan, Poland, Russia, Ukraine and the United States.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins